<DOC>
	<DOC>NCT01808092</DOC>
	<brief_summary>The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia</brief_summary>
	<brief_title>A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia</brief_title>
	<detailed_description>A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
	<criteria>18 to 90 years of age inclusive Females can participate if surgically sterile or completed menopause; if able to have children, must have negative serum pregnancy test, agree not to attempt pregnancy and use acceptable contraception while receiving study therapy and for 1 week after Onset of symptoms â‰¥ 48 hours after admission or &lt;7 days after discharge from an inpatient acute or chronic care facility New or worsening infiltrate on chest Xray obtained within 48 hours prior to randomization At least 1 of the following systemic signs:Fever (temperature &gt;38 C) or hypothermia (rectal/core temperature &lt;35 C); White blood cell count &gt;10,000 cells/mm3, or White blood cell count &lt;4500 cells/mm3, or &gt;15% band forms. Pulmonary disease that, in the investigator's judgment, would preclude evaluation of therapeutic response (e.g. lung cancer, active tuberculosis, cystic fibrosis, granulomatous disease, fungal pulmonary infection or recent pulmonary embolism). Patients with lung abscess, pleural empyema or post obstructive pneumonia. Patients with an estimated creatinine clearance &lt;16ml/min by Cockcroft Gault formula or patients expected to require haemodialysis or other renal support while on study therapy. Acute hepatitis in the prior 6 months, cirrhosis, acute hepatic failure or acute decompensation of chronic hepatic failure. Patients receiving hemodialysis or peritoneal dialysis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ceftazidime,</keyword>
	<keyword>Meropenem,</keyword>
	<keyword>Anti-Bacterial Agents,</keyword>
	<keyword>Anti-Infective Agents,</keyword>
	<keyword>Therapeutic Uses,</keyword>
	<keyword>Pharmacologic Actions,</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>